Depot and Sustained-Release Formulations

Why peptides need a smarter delivery system

Roughly 40 amino acids or fewer. That's the typical size range where a molecule stops behaving like a small drug and starts behaving like a peptide, and the pharmacokinetic headaches begin immediately. Peptides are enzymatically fragile. Plasma half-lives measured in minutes rather than hours are common (see our explainer on peptide half-life). The body is very good at dismantling them, which is elegant biology but a serious problem if you're trying to maintain a steady concentration at a target tissue. Sustained-release formulations exist to address exactly that problem.

That tension between biological activity and rapid clearance is what depot and sustained-release formulations exist to resolve. The chemistry here is genuinely fascinating, and I'd argue it's one of the more underappreciated areas of pharmaceutical science. Most of the public conversation about peptides in Australia circles around what they do rather than how they're made to last. That's the gap I want to fill here.

What "depot" actually means

A depot formulation is one that creates a physical reservoir of a drug at the site of administration, releasing the active molecule slowly over time. The word comes from the French for storage, which is exactly right. You're not dosing the bloodstream directly; you're creating a slow-supply depot that the body draws from.

The original depot concept was developed for steroid hormones and antipsychotics. Haloperidol decanoate, introduced in the 1970s, is a classic example; an oily intramuscular injection that releases the parent drug over two to four weeks. The principle has since been applied to peptides with considerable sophistication.

Sustained-release is a broader category. It covers any formulation engineered to extend the duration of drug exposure beyond what the unmodified molecule would achieve, through physical, chemical, or combined mechanisms. Depot is one type. Polymer microspheres, hydrogels, lipid matrices, and chemically modified prodrugs are others.

The pharmacokinetics problem (and why it's worse for peptides)

To understand why these technologies matter, it helps to appreciate what happens to an unprotected peptide after administration. Pharmacokinetics, absorption, distribution, metabolism, and excretion, plays out quickly and unfavourably. Peptidases in the blood and tissues cleave the peptide bonds between amino acids. Renal filtration removes smaller fragments. For many research peptides, the effective window of action is under an hour. A broader treatment is in our piece on peptide pharmacokinetics.

Compare that with a small-molecule oral drug, which might have a half-life of 8–24 hours and is absorbed through the gut over several hours to begin with. Peptides mostly can't be given orally anyway; the gastrointestinal tract destroys them before absorption, which is why most peptides are injectable and why subcutaneous injection is the standard route. But even injected subcutaneously, the molecule often clears before any sustained effect is possible.

The solution, broadly, is to slow the rate at which the active molecule enters systemic circulation. Three mechanisms dominate the published literature.

Three core mechanisms: how slow release is achieved

1. Polymeric microsphere and nanosphere systems

Biodegradable polymers, particularly poly(lactic-co-glycolic acid), known as PLGA, have been extensively studied as encapsulation matrices for peptides. The peptide is embedded within microspheres that degrade slowly through hydrolysis, releasing the payload over days to months depending on polymer composition and sphere size. PLGA degrades into lactic acid and glycolic acid, both natural metabolites, which is why it has regulatory acceptance in several approved formulations.

The release profile is not simply linear. PLGA systems often show an initial burst release as surface-associated peptide dissociates, followed by a lag phase, then a secondary release as bulk erosion accelerates. Controlling that burst is one of the more stubborn engineering challenges in this space; too much early release defeats the purpose; too little means inadequate initial exposure. Researchers have addressed it through surface coating, varying polymer molecular weight, and blending different PLGA grades.

2. Chemical modification: fatty acid conjugation and PEGylation

Rather than a physical carrier, this approach modifies the peptide molecule itself. Two strategies appear repeatedly in the literature.

Fatty acid conjugation binds a long-chain fatty acid to the peptide backbone. This exploits the high binding affinity of fatty acids for serum albumin; albumin effectively acts as a circulating depot, slowly releasing the free peptide over time. The GLP-1 receptor agonist class of compounds, researched extensively for metabolic applications, uses this principle. The fatty acid tether dramatically extends the pharmacokinetic half-life compared to the native GLP-1 peptide, which clears in under two minutes.

PEGylation attaches polyethylene glycol chains to the peptide. PEG is hydrophilic, flexible, and biologically inert; it creates a steric shield around the peptide that slows enzymatic degradation and reduces renal clearance by increasing hydrodynamic radius. The tradeoff is that large PEG chains can reduce receptor binding affinity, so the chemistry requires careful optimisation.

3. Hydrogel and lipid-based depots

Injectable hydrogels are polymer networks that exist as a liquid at room temperature but form a semi-solid gel at body temperature (or in response to pH). The peptide is dissolved in the liquid formulation, which gels at the injection site, then releases drug as the matrix swells, erodes, or undergoes diffusion. Poloxamer and chitosan systems have been investigated in this role.

Lipid-based depots, including lipid nanoparticles and liposomes, encapsulate peptides within lipid bilayers or lipid matrices. The lipid composition governs permeability and therefore release rate. These systems also offer some protection from plasma peptidases for the encapsulated fraction.

Regulatory classification of sustained-release formulations in Australia

This is where the science meets compliance, and the picture is more complicated than the chemistry. Any peptide-containing medicine in Australia must be assessed by the Therapeutic Goods Administration (TGA). Most therapeutic peptides fall under Schedule 4 (prescription only) under the Poisons Standard, with some falling under Schedule 8 as controlled drugs depending on structure and indication. Our guide to how peptides are scheduled in Australia covers the framework in more detail.

Sustained-release formulations are not a category that bypasses this framework. On the contrary, a novel depot formulation of a peptide requires its own regulatory assessment because the release profile, excipients, and manufacturing process all affect the safety and efficacy profile. An approved molecule in standard formulation is not automatically approved in a depot form. The TGA's evaluation of such products considers the full pharmacokinetic data package from the reformulation specifically.

For peptides marketed online for performance or cosmetic purposes, often as "research chemicals", the regulatory position in Australia is clear and worth stating plainly: many such products are unapproved therapeutic goods, and supplying them without TGA approval is illegal under the Therapeutic Goods Act 1989. The TGA has been actively enforcing against this market. The fact that a product uses sophisticated sustained-release chemistry doesn't change its legal status. Fancy encapsulation in an unapproved product is still an unapproved product.

For approved peptide medicines, access pathways include the Special Access Scheme and the Authorised Prescriber framework for unapproved therapeutic goods used under medical supervision. Products listed or registered on the ARTG are the baseline standard for general supply.

Bioavailability and the release profile relationship

I want to spend a moment on bioavailability because it gets conflated with "how much drug you absorb" when the fuller picture matters more for depot systems. Bioavailability is the fraction of an administered dose that reaches systemic circulation in an active form, but for a sustained-release formulation, the rate of bioavailability is as important as the extent. A slow, controlled input rate maintains plasma concentrations within a target range for longer, which is often the whole therapeutic rationale.

In vitro release testing, dissolving the formulation under controlled conditions and measuring drug appearance over time, is a standard early characterisation tool. The challenge is that in vitro correlates imperfectly with in vivo behaviour. The tissue microenvironment at an injection site, local enzyme activity, blood flow, and the foreign-body response to an implanted matrix all influence real-world release. This is one reason the regulatory data package for a novel depot requires in vivo pharmacokinetic data in addition to in vitro characterisation.

The engineering complexity of a single approved depot product represents years of optimisation that's completely invisible to the end user. A routine-looking injection can hide a great deal of formulation science. For the wider picture of how administration route shapes exposure, see routes of peptide delivery.

Where the research is heading

The published literature points toward a few active directions. Stimuli-responsive release systems, formulations that increase drug release in response to glucose concentration, pH shifts, or temperature changes, are being studied for metabolic peptides. The appeal is intuitive: a depot that releases more drug when blood glucose rises and less when it normalises is a fundamentally more intelligent delivery system than one releasing at a fixed rate regardless of physiology.

Microneedle patches are another area gaining momentum. These dissolve into the skin, depositing a polymer-encapsulated peptide payload in the dermal layer without a traditional needle. Early-stage work on insulin and GLP-1 analogues via this route has been published, though nothing is in widespread clinical use yet. The bioavailability questions for transdermal peptide delivery are still being worked through.

And honestly, first-pass metabolism avoidance through depot administration remains one of the cleaner arguments for the technology, not just for peptides but potentially for cannabinoid-based medicines too, where oral bioavailability and hepatic extraction are persistent formulation challenges. The underlying pharmacokinetic principles translate across compound classes.

Sources

• Therapeutic Goods Act 1989 Overview; TGA, Australian Government
• PLGA-based drug delivery systems for peptides and proteins, NCBI / National Library of Medicine
• Fatty acid conjugation strategies for extended half-life peptides, NCBI / National Library of Medicine
• Access to unapproved therapeutic goods; TGA, Australian Government

Priya Nandakumar, Pharmacology writer, peptides & PK